Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
C.L. Van der Poel, H.T. Cuypers, H.W. Reesink.
Hepatitis C virus six years on.
Lancet, 344 (1994), pp. 1475-1479
[2.]
J.H. Hoofnagle.
Hepatitis C: the clinical spectrum of disease.
Hepatology, 26 (1997), pp. 15S-20S
[3.]
V. Agnello, R.T. Chung, L.M. Kaplan.
A role for hepatitis C virus infection in type II cryoglobulinemia.
N Engl J Med, 327 (1992), pp. 1490-1495
[4.]
H. Lerat, S. Rumin, F. Habersetzer, F. Berby, M.A. Trabaud, C. Trepo, et al.
In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: influence of viral load, viral genotype, and cell phenotype.
Blood, 91 (1998), pp. 3841-3849
[5.]
L. Cocquerel, J.C. Meunier, A. Pillez, C. Wychowski, J. Dubuisson.
A retention signal necessary and sufficient for endoplasmic reticulum localization maps to the transmembrane domain of hepatitis C virus glycoprotein E2.
J Virol, 72 (1998), pp. 2183-2191
[6.]
A. Choukhi, A. Pillez, H. Drobecq, C. Sergheraert, C. Wychowski, J. Dubuisson.
Characterization of aggregates of hepatitis C virus glycoproteins.
J Gen Virol, 80 (1999), pp. 3099-3107
[7.]
J. Dubuisson.
Folding, assembly and subcellular localization of hepatitis C virus glycoproteins.
Curr Top Microbiol Immunol, 242 (2000), pp. 135-148
[8.]
N. Kato, H. Sekiya, Y. Ootsuyama, T. Nakazawa, M. Hijikata, S. Ohkoshi, et al.
Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus.
J Virol, 67 (1993), pp. 3923-3930
[9.]
Y. Chen, T. Maguire, R.E. Hileman, J.R. Fromm, J.D. Esko, R.J. Linhardt, et al.
Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate.
Nat Med, 3 (1997), pp. 866-871
[10.]
R. Thomssen, S. Bonk, A. Thiele.
Density heterogeneities of hepatitis C virus in human sera due to the binding of beta-lipoproteins and immunoglobulins.
Med Microbiol Immunol (Berl), 182 (1993), pp. 329-334
[11.]
R. Thomssen, S. Bonk, C. Propfe, K.H. Heermann, H.G. Kochel, A. Uy.
Association of hepatitis C virus in human sera with betalipoprotein.
Med Microbiol Immunol (Berl), 181 (1992), pp. 293-300
[12.]
V. Agnello, G. Abel, M. Elfahal, G.B. Knight, Q.X. Zhang.
Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor.
Proc Natl Acad Sci USA, 96 (1999), pp. 12766-12771
[13.]
S. Wunschmann, J.D. Medh, D. Klinzmann, W.N. Schmidt, J.T. Stapleton.
Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor.
J Virol, 74 (2000), pp. 10055-10062
[14.]
D. Rosa, S. Campagnoli, C. Moretto, E. Guenzi, L. Cousens, M. Chin, et al.
A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells.
Proc Natl Acad Sci USA, 93 (1996), pp. 1759-1763
[15.]
P. Pileri, Y. Uematsu, S. Campagnoli, G. Galli, F. Falugi, R. Petracca, et al.
Binding of hepatitis C virus to CD81.
Science, 282 (1998), pp. 938-941
[16.]
M. Flint, C. Maidens, L.D. Loomis-Price, C. Shotton, J. Dubuisson, P. Monk, et al.
Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81.
J Virol, 73 (1999), pp. 6235-6244
[17.]
T. Allander, X. Forns, S.U. Emerson, R.H. Purcell, J. Bukh.
Hepatitis C virus envelope protein E2 binds to CD81 of tamarins.
Virology, 277 (2000), pp. 358-367
[18.]
A. Meola, A. Sbardellati, B. Bruni Ercole, M. Cerretani, M. Pezzanera, A. Ceccacci, et al.
Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection.
J Virol, 74 (2000), pp. 5933-5938
[19.]
X. Forns, T. Allander, P. Rohwer-Nutter, J. Bukh.
Characterization of modified hepatitis C virus E2 proteins expressed on the cell surface.
Virology, 274 (2000), pp. 75-85
[20.]
L. Cocquerel, C. Wychowski, F. Minner, F. Penin, J. Dubuisson.
Charged residues in the transmembrane domains of hepatitis C virus glycoproteins play a major role in the processing, subcellular localization, and assembly of these envelope proteins.
J Virol, 74 (2000), pp. 3623-3633
[21.]
R. Oren, S. Takahashi, C. Doss, R. Levy, S. Levy.
TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins.
Mol Cell Biol, 10 (1990), pp. 4007-4015
[22.]
M.D. Wright, M.G. Tomlinson.
The ins and outs of the transmembrane 4 superfamily.
Immunol Today, 15 (1994), pp. 588-594
[23.]
F. Berditchevski, M.M. Zutter, M.E. Hemler.
Characterization of novel complexes on the cell surface between integrins and proteins with 4 transmembrane domains (TM4 proteins).
Mol Biol Cell, 7 (1996), pp. 193-207
[24.]
H.T. Maecker, S.C. Todd, S. Levy.
The tetraspanin superfamily: molecular facilitators.
Faseb J, 11 (1997), pp. 428-442
[25.]
G. Horvath, V. Serru, D. Clay, M. Billard, C. Boucheix, E. Rubinstein.
CD19 is linked to the integrin-associated tetraspans CD9, CD81, and CD82.
J Biol Chem, 273 (1998), pp. 30537-30543
[26.]
P. Hausfater, E. Rosenthal, P. Cacoub.
Lymphoproliferative diseases and hepatitis C virus infection.
Ann Med Interne (Paris), 151 (2000), pp. 53-57
[27.]
A. Wack, E. Soldaini, C. Tseng, S. Nuti, G. Klimpel, S. Abrignani.
Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-stimulatory signal for human T cells.
Eur J Immunol, 31 (2001), pp. 166-175
[28.]
S.C. Todd, S.G. Lipps, L. Crisa, D.R. Salomon, C.D. Tsoukas.
CD81 expressed on human thymocytes mediates integrin activation and interleukin 2-dependent proliferation.
J Exp Med, 184 (1996), pp. 2055-2060
[29.]
C.T. Tseng, G.R. Klimpel.
Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions.
J Exp Med, 195 (2002), pp. 43-50
[30.]
S. Crotta, A. Stilla, A. Wack, A. D'Andrea, S. Nuti, U. D'Oro, et al.
Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein.
J Exp Med, 195 (2002), pp. 35-42
[31.]
J.G. McHutchison, S.C. Gordon, E.R. Schiff, M.L. Shiffman, W.M. Lee, V.K. Rustgi, et al.
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.
N Engl J Med, 339 (1998), pp. 1485-1492
[32.]
S. Levy, S.C. Todd, H.T. Maecker.
CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system.
Annu Rev Immunol, 16 (1998), pp. 89-109
[33.]
S. Takikawa, K. Ishii, H. Aizaki, T. Suzuki, H. Asakura, Y. Matsuura, et al.
Cell fusion activity of hepatitis C virus envelope proteins.
J Virol, 74 (2000), pp. 5066-5074
[34.]
K. Meyer, A. Basu, R. Ray.
Functional features of hepatitis C virus glycoproteins for pseudotype virus entry into mammalian cells.
Virology, 276 (2000), pp. 214-226
[35.]
Y. Matsuura, H. Tani, K. Suzuki, T. Kimura-Someya, R. Suzuki, H. Aizaki, et al.
Characterization of pseudotype VSV possessing HCV envelope proteins.
Virology, 286 (2001), pp. 263-275
[36.]
R. Petracca, F. Falugi, G. Galli, N. Norais, D. Rosa, S. Campagnoli, et al.
Structure-function analysis of hepatitis C virus envelope-CD81 binding.
J Virol, 74 (2000), pp. 4824-4830
[37.]
M. Flint, J.A. McKeating.
The role of the hepatitis C virus glycoproteins in infection.
Rev Med Virol, 10 (2000), pp. 101-117
[38.]
B. Kronenberger, B. Ruster, R. Elez, S. Weber, A. Piiper, J.H. Lee, et al.
Interferon alfa down-regulates CD81 in patients with chronic hepatitis C.
Hepatology, 33 (2001), pp. 1518-1526
[39.]
P. Sanz-Cameno, P. Majano, C. Garcia-Monzon, O. Lo Iacono, M.J. Borque, R. Moreno-Otero.
Expresion de integrinas β1, CD81 y otras tetraspan en lineas celulares hepaticas: interaccion con la glicoproteina E2 del virus de la hepatitis C (VHC).
Gastroenterol Hepatol, 24 (2001), pp. 89A
Copyright © 2002. Elsevier España, S.L.. Todos los derechos reservados
